Patients left behind: Rare dermatologic conditions miss the orphan drug development boom

To the Editor: Orphan drugs are those indicated for the treatment of uncommon conditions and are granted 7 years of exclusivity by the US Food and Drug Administration. As a result of this designation, there has been a considerable increase in rare disease research, pharmaceutical development, and market expenditures1Kakkar A.K. Dahiya N. Strategic commentary: the evolving drug development landscape: from blockbusters to niche busters in the...